The newly raised capital will be deployed across strategic priorities, including a nationwide distribution expansion across D2C, quick commerce, modern trade, pharmacy and other retail channels
TruNativ, a science-backed everyday nutrition company, has closed its funding round of around USD 30 million, led by OrbiMed, a dedicated healthcare investment firm. The series B funding round comprised both primary investment and the sale of secondary shares of early investors.
The newly raised capital will be deployed across strategic priorities, including a nationwide distribution expansion across direct-to-consumer (D2C), quick commerce, modern trade, pharmacy and other retail channels. The company also plans to expand its B2B2C ingredient business, which currently powers nutrition solutions for several leading consumer brands in India.
“For decades, Indian consumers have been underserved: overexposed to sugar, protein deficiency and dependent on products that promise health but deliver compromise. We built TruNativ to fix that for every household, not just the health-conscious few. OrbiMed’s investment signals that preventive nutrition is no longer a wellness trend, it is a healthcare imperative,” stated Pranav Malhotra, Co-founder and Chief Executive Officer, TruNativ.
The company added that as consumers increasingly prioritise healthier lifestyles and proactive wellness, demand for clean-label, science-backed nutrition solutions continues to accelerate. TruNativ is looking to capitalise on this opportunity and shape the future of everyday nutrition in India. PwC acted as exclusive financial advisor to TruNativ on this transaction.
“We share Pranav’s passion for improving nutrition nationwide and enhancing health outcomes through healthier daily dietary habits. OrbiMed is excited to partner with TruNativ as it builds a leading consumer health business,” said Sunny Sharma, Senior Managing Director, OrbiMed Asia.
